GlassScriptPhysician profile
David M Druskin
NPI 1396805081
$1,329.04
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.92 · 2022: $639 · 2023: $307 · 2024: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.02 | 2022-2024 | |
| Amgen INC. | $176.71 | 2021-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $171.66 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $132.51 | 2022-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $83.27 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $79.13 | 2022-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $51.89 | 2022 | |
| Corium, LLC | $47.92 | 2022 | |
| Idorsia Pharmaceuticals US INC | $43.27 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $31.22 | 2022 | |
| Neos Therapeutics, LP | $27.68 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.85 | 2024 | Xifaxan, Trulance |
| Pfizer INC. | $21.82 | 2024 | |
| Exact Sciences Corporation | $18.10 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $16.55 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.25 | 2022 | |
| Genentech USA, INC. | $16.15 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.66 | 2022 | |
| Medtronic, INC. | $15.35 | 2022 | |
| Biodelivery Sciences International, INC. | $15.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Druskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.